Investor Relations

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Investor Relations

KemPharm uses its LAT™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing
Toggle Summary KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201

View more

Upcoming Events

Date Event Details Remind Me
Summary Toggle Jun 15, 2021 at 3:00 PM EDT

BIO Digital 2021
Panel:    Lessons from COVID on Innovation, Collaboration & Enforcement
Add to Outlook
Add to Google Calendar

View more

Letter to Shareholders

Travis C. Mickle, Ph.D.
Chairman, President, Chief Executive Officer and Shareholder
KemPharm, Inc.

Download